cystic fibrosis | mecfa 22/28

MECFA Blog

Pancreatic Cell Transplant Program Offers New Hope to Some CF Patients

The University of North Carolina (UNC) is among only a few institutions in the United States that offers patients with inflamed pancreas...

WVU Medicine Granted CFF Accreditation for its Adult Cystic Fibrosis Program

The Adult Cystic Fibrosis Program at West Virginia University Medicine’s Mountain State Cystic Fibrosis Center was recently awarded...

Award granted to Neem Biotech to develop antimicrobial intervention for chronic lung infections

Neem Biotech, a Wales based R&D pharmaceutical biotech working in the field of novel antimicrobial drug development, is pleased to...

Understanding How Bacteria ‘Talk’ Could Hold Key for New CF Treatments, Study Suggests

New research provides insights into how bacteria “talk” to each other in lung infections, which could provide strategies to block these...

#ECFS2018 – 3 Scientists Win 2018 ‘Young Investigators Awards’ for Innovative CF Research

The European Cystic Fibrosis Society presented three scientists — one Portuguese, one Mexican, and one German — with the organization’s...

#ECFS2018 – AB-PA01, with Antibiotics, Shows Promise in Treating Drug-resistant Lung Infections in C

AmpliPhi Biosciences’ investigative therapy AB-PA01, in combination with antibiotics, shows significant potential to treat multi-drug...

PTI-808

PTI-808 is an experimental therapy being developed by Proteostasis Therapeutics to treat the most common type of cystic fibrosis (CF)...

Cystic Fibrosis Medications: What You Need to Know

Cystic fibrosis is a life-threatening, genetic disease that affects patients’ ability to breathe and is marked by persistent lung...

Way Found to Use Antimicrobial Peptides, Part of Immune System, to Treat Bacterial Lung and Wound In

Antimicrobial peptides administered as tiny nanoparticles show promise in treating bacterial infections without risking making the...

Vast Therapeutics’ Therapy Candidate BIOC51 Fares Well in Mouse Studies

Vast Therapeutics, formerly known as Novoclem Therapeutics, recently announced that the company’s first controlled nitric oxide (NO)...

Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds

VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE

A case for improved carrier screening

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data

Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS

Age May Affect Outcomes in Lung Transplant Recipients With Cystic Fibrosis

CFF Funding Will Further ContraFect’s Research Into Alternative for Antibiotics

The search for molecular glue in targeted disease control

Vest Therapy Lowers Risk of Hospitalization in Non-CF Bronchiectasis, Study Says

Harvard is working with Boston hospitals to test existing cystic fibrosis drug to help coronavirus p